comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 01:14:02 - browse：41

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Roche's accidental data boosts hopes for anti

Wikipedia

WSS

The battle over the Brookhaven Landfill on Long Island

FDA greenlights medical device to combat bladder issues

Colonoscopy at 40? Study finds a possible benefit

National associations that represent hospice owe an apology

National associations that represent hospice owe an apology

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

hotspot

comprehensive

focus

How one medical school became remarkably diverse

National associations that represent hospice owe an apology

Malaria cases in Florida and Texas: Here’s what you need to know

Death of patient in Alzheimer’s trial raises question of possible risks

Wildfire smoke exposes gaps in outdoor worker protections

Republicans love RFK Jr. What's that tell us about health in 2024?

Continuity nursing helped my family in our darkest PICU moments

Why we need to separate burnout from moral injury in health care

The high cost of giving birth even with insurance

Health officials lay out plans to cope with respiratory virus season

leisure time

FDA greenlights medical device to combat bladder issues

The story of mRNA: From a loose idea to a tool that may help curb Covid

FDA greenlights medical device to combat bladder issues

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Donald Trump's relentless attacks on special counsel Jack Smith

FDA advisory panel to debate high blood pressure devices

Wikipedia

Wikipedia

explore

Wikipedia